

सं0 / No.31026/39/2020-Scheme(Pt.2)  
भारत सरकार / Government of India  
रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers  
औषध विभाग / Department of Pharmaceuticals

\*\*\*\*\*

शास्त्री भवन, नई दिल्ली  
Shastri Bhawan, New Delhi  
Dated the 26<sup>th</sup> July, 2022

**शुद्धिपत्र/CORRIGENDUM**

Subject:- Required Modifications in the Guidelines of Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates and Active Pharmaceuticals Ingredients (APIs) in the Country to invite application for the eligible product Vitamin B1, through chemical synthesis route – reg.

As per the guidelines dated 29.10.2020 for the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates and Active Pharmaceuticals Ingredients (APIs) in the Country, applications were invited under the Scheme under three rounds.

2. Subsequent to the decision in Empowered Committee (EC) meeting on 03.06.2022, actions are to be taken to invite application for the eligible product Vitamin B1, through chemical synthesis route. As per the decision taken, the 10% incentive rate shall be applicable as applicable for APIs produced through Chemical Synthesis and the Incentive ceiling for vitamin B1 will remain the same as per original guidelines.

3. In this regard, the necessary modifications in the Appendix B and Appendix E in the existing guidelines **for the product Vitamin-B1** are as follows:

S. No.	Appendix	Existing Guidelines	Revised Amendment in Guidelines
1	Appendix-B	Vitamin-B1 at Sl. No. 11 in <i>Fermentation based niche KSMs / Drug Intermediates / APIs</i> and	Existing Sl.No.11 is deleted Serial Numbers from 12 to 41 are re-organized as Serial Numbers 11 to 40 <b>and following entry is made at Sl. No. 41 –</b>



		Minimum annual production Capacity (Metric Tonnes) – 200 MT Maximum number of applicants to be selected – 2.	Vitamin B1 in <b><i>Other Chemical Synthesis based KSMs / Drug Intermediates / APIs</i></b> and Minimum annual production Capacity (Metric Tonnes) – 200 MT Maximum number of applicants to be selected – 2
2	<b>Appendix-E (Table-2)</b>	Sl. No. 11 – Vitamin B1 in <b><i>Fermentation based niche KSMs / Drug Intermediates / APIs</i></b> and  Maximum number of applicants to be selected – 2	<b>Existing Sl.No.11 is deleted</b> Serial Numbers from 12 to 41 are re-organized as Serial Numbers 11 to 40 <b>and following entry is made at Sl. No. 41 –</b> Sl. No. 41 – Vitamin B1 in <b><i>Other Chemical Synthesis based KSMs / Drug Intermediates / APIs</i></b> and  Maximum number of applicants to be selected – 2
		<b>Rate of Incentive (in %) –</b> FY 2023-24 to FY 2026-27: <b>20 %</b> , FY 2027-28: <b>15 %</b> , FY 2028-29: <b>5 %</b>	<b>Rate of Incentive (in %) –</b> FY 2023-24 to FY 2027-28 – <b>10 %</b>
		<b>Maximum incentive per annum (Rs. Crore) –</b> FY 2023-24 to FY 2026-27: <b>20</b> , FY 2027-28: <b>15</b> , FY 2028-29: <b>5</b>	<b>Maximum incentive per annum (Rs. Crore)</b> FY 2022-23 – <b>0*</b> FY 2023–24 to FY 2027-28: <b>20</b>
		<b>Maximum incentive for each selected applicant per annum (Rs. Crore)*</b> FY 2023-24 to FY 2026-27: <b>10</b> , FY 2027-28: <b>7.5</b> , FY 2028-29: <b>2.5</b>	<b>Maximum incentive for each selected applicant per annum (Rs. Crore)*</b> FY 2022-23 – <b>0*</b> FY 2023–24 to FY 2027-28: <b>10</b>

\*-FY 22-23 is the installation year, as applications are being invited



4. Due to the above, the resultant changes in other annexures are as below;

S. No.	Existing Guidelines	Revised Amendment in Guidelines
1	<b>Appendix E (Table - 1)</b>  Number of Product <b>10 Fermentation based niche KSMs / Drug Intermediates / APIs</b>  FY 23-24 Rs. 200 cr FY 24-25 Rs. 200 cr FY 25-26 Rs. 200 cr FY 26-27 Rs. 200 cr FY 27-28 Rs. 150 cr FY 28-29 Rs. 50 cr  <b>Total :- Rs. 1000 cr</b>	<b>Appendix E (Table - 1)</b>  Number of Product <b>9 Fermentation based niche KSMs / Drug Intermediates / APIs</b>  FY 23-24 Rs. 180 cr FY 24-25 Rs. 180 cr FY 25-26 Rs. 180 cr FY 26-27 Rs. 180 cr FY 27-28 Rs. 135 cr FY 28-29 Rs. 45 cr  <b>Total :- Rs. 900 cr</b>
2	<b>Appendix E (Table - 1)</b>  Number of Product <b>23 Chemical Synthesis based KSMs / Drug Intermediates / APIs</b>  FY 22-23 Rs. 230 cr FY 23-24 Rs. 230 cr FY 24-25 Rs. 230 cr FY 25-26 Rs. 230 cr FY 26-27 Rs. 230 cr FY 27-28 Rs. 230 cr FY 28-29 Rs. Nil  <b>Total :- Rs. 1380 cr</b>	<b>Appendix E (Table - 1)</b>  Number of Product <b>24 Chemical Synthesis based KSMs / Drug Intermediates / APIs</b>  FY 22-23 Rs. 230 cr FY 23-24 Rs. 250 cr FY 24-25 Rs. 250 cr FY 25-26 Rs. 250 cr FY 26-27 Rs. 250 cr FY 27-28 Rs. 250 cr FY 28-29 Rs. Nil  <b>Total :- Rs. 1480 cr</b>

5. All other clauses of the guidelines dated 29.10.2010 remains the same. Detailed guidelines of the Scheme are available at <https://pharmaceuticals.gov.in/schemes>. The eligible applicants may apply through online only (<https://plibulkdrugs.ifcilttd.com>) and it is requested to make necessary changes in the IT system of the PLI scheme in this regard.





6. This issues with the approval of the competent authority.

*Uma Magesh*

(Uma Magesh)

Under Secretary to the Govt. of India

Tel:- 23383392

Email: - uma.magesh@nic.in

To

- (i) Shri Prasoon, Chief Financial Officer, IFCI Limited, IFCI Tower, 61, Nehru Place, New Delhi- 110019 , Email: [prasoon@ifcilttd.com](mailto:prasoon@ifcilttd.com)
- (ii) Director, NIC, DoP - with a request to upload the same in the DoP website